Search
HARVONI 90 MG / 400 MG, Comprimé pelliculés
Details
| --- | Description |
|---|---|
| Pack | Flacon de 28 |
| Strength (Dosage) | 90 MG | 400 MG |
| Laboratory | AFRIC-PHAR |
| Ingredients | Sofosbuvir | Lédispasvir |
| Therapeutic class | Antiviral, anti-VHC, double association |
| ATC code | J05AP51 |
| PPH | $488.70 |
| PPV | $514.70 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | Harvoni est indiqué pour le traitement de l’hépatite C chronique (HCC) chez les adultes et les adolescents âgés de 12 ans à moins de 18 ans |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem